We are live on ! Find out more
IMGO

Imago BioSciences, Inc. Common stock

Delisted

IMGO was delisted on the 10th of January, 2023.

59 hedge funds and large institutions have $576M invested in Imago BioSciences, Inc. Common stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

13% more funds holding

Funds holding: 5259 (+7)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less capital invested

Capital invested by funds: $607M → $576M (-$30.9M)

Holders
59
Holders Change
+7
Holders Change %
+13.46%
% of All Funds
0.93%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
13
Increased
26
Reduced
14
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$93.4M +$41.5M +1,998,411 +70%
BlackRock
2
BlackRock
New York
$63.4M +$40.5M +1,954,112 +146%
OFM
3
Omega Fund Management
Massachusetts
$58.2M
FLSM
4
Frazier Life Sciences Management
California
$57.3M +$61.6M +2,971,274 New
Citadel Advisors
5
Citadel Advisors
Florida
$48.1M +$944K +45,495 +2%
FCM
6
Farallon Capital Management
California
$47.6M
Blackstone Inc
7
Blackstone Inc
New York
$47M -$19.5M -938,305 -28%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$41.9M -$1.45M -69,682 -3%
WP
9
Woodline Partners
California
$16M -$338K -16,299 -2%
Vanguard Group
10
Vanguard Group
Pennsylvania
$15.3M +$6.71M +323,376 +69%
EA
11
Emerald Advisers
Pennsylvania
$11.9M +$834K +40,209 +7%
SG
12
StepStone Group
California
$10.1M
EMFAT
13
Emerald Mutual Fund Advisers Trust
Pennsylvania
$9.76M -$706K -34,006 -6%
DCM
14
Driehaus Capital Management
Illinois
$6.84M -$141K -6,816 -2%
MCMC
15
Matrix Capital Management Company
New Hampshire
$5.94M +$6.39M +308,044 New
Adage Capital Partners
16
Adage Capital Partners
Massachusetts
$5.3M
Geode Capital Management
17
Geode Capital Management
Massachusetts
$5.09M +$2.06M +99,425 +60%
KCM
18
Kingdon Capital Management
New York
$5.01M +$1.79M +86,288 +50%
State Street
19
State Street
Massachusetts
$4.99M +$2.24M +108,040 +72%
Northern Trust
20
Northern Trust
Illinois
$3.4M +$1.44M +69,211 +65%
PHP
21
Parkman Healthcare Partners
Connecticut
$2.69M +$617K +29,751 +27%
Goldman Sachs
22
Goldman Sachs
New York
$1.83M +$147K +7,065 +8%
AP
23
AlpInvest Partners
Netherlands
$1.74M +$1.88M +90,469 New
JP Morgan Chase
24
JP Morgan Chase
New York
$1.21M +$1.16M +55,964 +828%
TD Asset Management
25
TD Asset Management
Ontario, Canada
$1.11M +$776K +37,400 +183%

IMGO Hedge Fund Activity: Q1 2022 in Review

59 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Imago BioSciences, Inc. Common stock (IMGO) for Q1 2022, worth a combined $576M — down 5.1% from $607M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IMGO positions and 6 closed out — a net gain of 7 holders — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $41.5M. The largest seller was Frazier Management, exiting entirely with an estimated $70.4M sold.

  • 59 institutional investors held Imago BioSciences, Inc. Common stock (IMGO) as of Q1 2022, up from 52 in Q4 2021.
  • Funds reported $576M of Imago BioSciences, Inc. Common stock stock for Q1 2022, down 5.1% quarter-over-quarter.
  • 13 funds opened new Imago BioSciences, Inc. Common stock positions in Q1 2022 and 6 closed out, a net change of +7 holders.
  • The largest Imago BioSciences, Inc. Common stock buyer in Q1 2022 was Fidelity Investments, an estimated $41.5M added.
  • The largest Imago BioSciences, Inc. Common stock seller in Q1 2022 was Frazier Management, an estimated $70.4M sold.

Based on aggregated 13F filings for Q1 2022.